Calamos Advisors
PVLA

Calamos Advisors’s Palvella Therapeutics PVLA Stock Holding History

Calamos Advisors’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.6M Buy
10,479
+675
+7% +$81.9K 0.01% 687
2026
Q1 		$1.22M Buy
+9,804
New +$1.02M ﹤0.01% 740

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Calamos Advisors's PVLA Position: Q2 2026 in Review

Calamos Advisors increased its Palvella Therapeutics (PVLA) stake by 6.9% in Q2 2026, buying an estimated $81.9K and bringing the position to 10,479 shares worth $1.6M. The position accounts for 0.01% of the portfolio, ranked #687.

Calamos Advisors first reported a position in PVLA in Q1 2026 and has held it in 2 quarters since. 197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Calamos Advisors held 10,479 shares of Palvella Therapeutics worth $1.6M as of Q2 2026.
  • Calamos Advisors bought 675 Palvella Therapeutics shares in Q2 2026, an estimated $81.9K.
  • Palvella Therapeutics made up 0.01% of Calamos Advisors's portfolio in Q2 2026, its #687 holding.
  • Calamos Advisors first reported a position in Palvella Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Calamos Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.